Clinical trial
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
ClinicalTrials.gov ID: NCT01721746
Sponsor: Bristol-Myers Squibb
Information provided by: Bristol-Myers Squibb (Responsible Party)
Last Update Posted: 2022-04-19
Brief Summary:
The purpose of the study is to estimate the response rate and compare overall survival of patients taking BMS-936558 to those taking study physician's choice of either Dacarbazine or Carboplatin and Paclitaxel
Official Title:
A Randomized Open-Label Phase 3 Trial of BMS-936558 (Nivolumab) Versus Investigator's Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy
Intervention / Treatment:
- Biological: BMS-936558
- Drug: Dacarbazine
- Drug: Carboplatin
- Drug: Paclitaxel
| Category | Value |
|---|---|
| Study Start (Actual) |
2012-12-21
|
| Primary Completion (Estimated) |
2016-02-16
|
| Study Completion (Estimated) |
2020-12-29
|
| Enrollment (Estimated) | 405 |
| Study Type | Interventional |
| Phase | Phase 3 |
| Other Study ID Numbers |
CA209-037
2012-001828-35 (EudraCT Number) |